Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87
- Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays - Natalie Phelps, whose clinical trial was delayed due to RIFs, dies of colon cancer
- Shane Jacobson talks about his to-do list for ACS
Boost research, forge closer ties with cancer centers, launch an all-out campaign for resources - My introduction to, and lessons learned from, Rick Pazdur









